Natalizumab: clinical use
Evidence-based neurology checklist on natalizumab: clinical use: Mode of action Natalizumab is a humanised monoclonal antibody It binds to α4β1-integrin on the surface of lymphocytes and monocytes It thereby inhibits lymphocyte migration into the central nervous system The effect lasts up to 6…
Mode of action
- Natalizumab is a humanised monoclonal antibody
- It binds to α4β1-integrin on the surface of lymphocytes and monocytes
- It thereby inhibits lymphocyte migration into the central nervous system
- The effect lasts up to 6 months
Clinical benefits of Natalizumab
Dose
Acronym
References
- Dargahi N, Katsara M, Tselios T, et al. Multiple sclerosis: immunopathology and treatment update. Brain Sci 2017; 7(7) pii: E78.
- Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relapsing multiple sclerosis. BMJ 2016; 354:i3518.
- Vargas DL, Tyor WR. Update on disease-modifying therapies for multiple sclerosis. J Investig Med 2017; 65:883-891.
- Stuve O, Marra CM, Cravens PD, et al. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy. Arch Neurol 2007; 64: 169-176.
- Warnke C, Menge T, Hartung H-P, et al. Natalizumab and progressive multifocal leukoencephalopathy. Arch Neurol 2010; 67:923-930.
- And 3 more. Subscribe to see the full list
